The vehicle is one of the most valuable assets most Americans own. Now it has a home inside the app where they manage the rest of their money.

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- For many Americans, the vehicle in the driveway is one of their most valuable assets and, between loan or lease payments, insurance, and gas, also one of their biggest monthly expenses. Yet its full financial picture — what it's worth, what's owed, loan payoff timeline, insurance information — has always been scattered and incomplete, leaving most owners without the data they need to make smarter decisions.

Today, OnePay, the consumer fintech trusted by millions of Americans to make money better, announced the launch of My Garage. Consumers can have access to an up to date vehicle value, loan equity, payoff timeline, auto insurance offers, and gas rewards, all in one place inside the app where they manage the rest of their financial lives.

Instead of hunting across multiple apps for a partial picture, consumers can have one clear financial view into their vehicle. They can watch their payoff timeline shorten as they move toward owning their vehicle outright, and soon will be able to compare auto loan refinance rates. Further, they can compare insurance offers, access gas rewards and more, all without leaving the app.

"Consumers don't think in terms of financial products. They think about what those products make possible in their lives. And for millions of Americans, owning a car unlocks opportunities. My Garage is about giving people financial visibility into one of the most expensive assets they own but rarely fully understand," said Pat McLoughlin, GM of Marketplace at OnePay.

My Garage begins rolling out to OnePay customers today.

About OnePay

OnePay is an all-in-one financial services platform built on the simple belief that better money makes life better. With banking, high-yield savings, credit cards, point-of-sale lending, investment and crypto offerings, OnePay is providing millions of consumers with the tools they need to holistically manage their financial lives in one place. Alongside its expanding consumer offering, OnePay also partners with employers, HCM providers, gig platforms, and others to deliver embedded financial services to millions of employees and frontline workers.

OnePay is a financial technology company, not a bank. Banking services through OnePay are provided by Coastal Community Bank or Lead Bank, Members FDIC. OnePay debit and credit cards (including the Builder Mastercard®) are issued by partner banks pursuant to licensing by Mastercard® International. Brokerage services through OnePay are provided by One Growth Securities LLC, member FINRA/SIPC. Crypto services through OnePay powered by Zero Hash LLC and Zero Hash Liquidity Services LLC through an agreement with OneProgress Assets LLC. Investment and crypto products are not FDIC Insured, not bank guaranteed and may lose value. One Growth Securities LLC does not provide crypto services and OneProgress Assets LLC is not a member of FINRA/SIPC.

Media contact

press@onepay.com

SOURCE OnePay

Share this article

AMHERST, Mass., Sept. 2, 2026 /PRNewswire/ -- UMass Athletics and Baystate Health, in collaboration with Learfield's UMass Sports Properties, announced today an expanded, multi-year partnership that will bring new on-field branding and additional fan engagement opportunities to UMass Athletics.

The expanded partnership brings together two of the region's largest employers and well-known organizations – UMass Amherst and Baystate Health – who already have a strong academic and clinical relationship and are deeply connected in the community. Each semester, Baystate Health hosts UMass undergraduate students for clinical placements across its hospitals, offering preceptorships for many seniors, and clinical hours for graduate students pursuing advanced degrees. Baystate Nursing Research collaborates with the Elaine Marieb Center for Nursing and Engineering Innovation to support nurse-led research and innovation. This fall, Baystate and UMass Amherst launched an internship program for students interested in careers in business-related fields, including marketing and finance. Together, UMass Amherst and Baystate Health are investing in thousands of employees, students, patients, families, and fans across the region, to strengthen community connections, invest in the region and help generations thrive.

"UMass Amherst and Baystate Health have done much together over the decades, and this is a unique opportunity to further strengthen a longstanding partnership," said Peter D. Banko, President & CEO of Baystate Health. "We are excited to deepen our support of UMass, its athletic programs, and its student athletes and hope this can be the impetus for other organizations to join us in advancing communities across Western Massachusetts."

Beginning with the 2026 football season, the Baystate Health logo will be featured on both 25-yard lines at McGuirk Alumni Stadium, the home of Minuteman football since 1965. The new placement marks the first time a brand's logo will be featured on the gridiron and a significant expansion of the health system's longstanding partnership with UMass Athletics.

"Baystate Health has been an outstanding partner of Massachusetts Athletics for more than a decade, and we're excited to keep growing that partnership for years to come," said Director of Athletics Ryan Bamford. "Baystate Health's commitment reflects a shared investment in the health, well-being and success of our more than 650 student-athletes and the broader UMass community. We're grateful for the continued support and look forward to achieving even more together."

Baystate Health will also have a presence across UMass hockey and men's and women's basketball with prominent branding throughout the Mullins Center, including the 'Baystate Benches' featuring exclusive signage behind both hockey benches. The partnership also expands the Junior Captain of the Game, a fan-favorite UMass Hockey promotion, to include every home football and hockey game throughout the 2026-27 season. The program gives local aspiring young athletes and dedicated fans (ages 6 to 12 years) the opportunity to be recognized as Junior Captain and join the team for a memorable gameday experience, alongside in-game recognition and social media enter-to-win sweepstakes opportunities for UMass fans.

With a workforce of nearly 13,000 team members, Baystate Health is an economic and health pillar in Western Massachusetts serving over 800,000 people. The partnership connects the integrated health system with a passionate UMass fan base in the region. According to Learfield's Fanbase platform, the largest proprietary fan data database in college athletics, more than 325,000 UMass fans live within 10 miles of a Baystate Health location, while nearly half of all UMass fans visited Baystate Medical Center in the past 12 months.

"Baystate Health and UMass Athletics have deep roots in Western Massachusetts, making this a natural partnership with tremendous potential to connect with the local community," said Andrew Stuebner, General Manager of UMass Sports Properties. "We are proud to help build partnerships that are not only highly visible but strategically aligned with the communities and audiences our partners want to reach."

UMass Sports Properties, the locally based team of Learfield – the leading media and technology company powering college sports – is the exclusive multimedia rights holder for UMass Athletics and handles all sponsorships, in-venue signage, and advertising on behalf of the university.

About UMass Athletics

Massachusetts Athletics is home to 21 NCAA Division I programs and more than 650 student-athletes. who proudly represent the Commonwealth. Guided by its mission to Educate, Win, Inspire and Invest, the department is committed to developing champions in competition, the classroom and the community through strategic investments in people, programs and facilities. That commitment is reflected in our student-athletes' sustained academic excellence, highlighted by a school-record NCAA Academic Progress Rate (APR) score of 995 for the 2024-25 academic year and 20 consecutive semesters with a departmental GPA above 3.0. As a proud member of the Mid-American Conference, Hockey East, the Atlantic 10 (men's lacrosse), the Summit League (men's soccer) and the Missouri Valley Conference (men's swimming and diving), Massachusetts Athletics continues to elevate its programs while building meaningful connections with alumni, fans, corporate partners and communities throughout New England and beyond.

About Baystate Healthcare

Baystate Health is a not-for-profit, integrated healthcare system with hospitals, physician practices, a health plan and more serving over 800,000 people throughout western New England. Baystate Health is the safety net provider in Western Massachusetts. With roots dating to the founding of Springfield Hospital in 1883, Baystate Health has been providing high-quality, compassionate and accessible care in the Pioneer Valley for more than 140 years and continues to be a pillar of its community – rooted here, serving here, and helping generations thrive here. With a focus on advancing health for all, Baystate is not only a keystone of the region, it is a national leader in healthcare. Learn more at BaystateHealth.org.

About Learfield

Learfield is the leading media and technology company powering college athletics. Through its digital and physical platforms, Learfield owns and leverages a deep data set and relationships in the industry to drive revenue, growth, brand awareness, and fan engagement for brands, sports, and entertainment properties. With ties to over 1,200 collegiate institutions and over 12,000 local and national brand partners, Learfield's presence in college sports and live events delivers influence and maximizes reach to target audiences. With solutions for a 365-day, 24/7 fan experience, Learfield enables schools and brands to connect with fans through licensed merchandise, game ticketing, donor identification for athletic programs, exclusive custom content, innovative marketing initiatives, NIL solutions, and advanced digital platforms. Since 2008, it has served as title sponsor for the acclaimed Learfield Directors' Cup, supporting athletic departments across all divisions.

SOURCE Baystate Health System

Share this article

- Morgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B

- The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader portfolio of businesses to tackle distinct parts of the oncology journey

NASHVILLE, Tenn., Sept. 2, 2026 /PRNewswire/ -- Thyme Care, the nationally recognized oncology company, today announced a new Series E financing round of over $125M. Morgan Health led the round, with participation from strategic healthcare investors Humana and CVS Health Ventures, as well as institutional investors AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health.

The financing brings together strategic investors from across the cancer care ecosystem, including the largest national payers, community oncology, health systems, and leaders in employer-sponsored health care, reflecting favorable investor outlook on Thyme Care's care model and its potential to take on the broader challenges in cancer care. Today, Thyme Care services are available to more than 10.5 million people across all 50 states, and the company manages more than $7 billion in oncology spend. By aligning care around the patient, the model delivers 5 to 10 percent validated reductions in total cost of care, creating measurable value for patients, providers, and health plan partners. Supported by strong financial discipline, Thyme Care is profitable, generates meaningful positive free cash flow, and is positioned to accelerate its next phase of growth.

"People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs," said Dan Mendelson, chief executive officer of Morgan Health. "We're continuing to invest in Thyme Care because we're confident they can continue to deliver value to patients and payers – as they make the next wave of cancer care innovation easier to access and navigate."

Alongside the Series E, Thyme Care is establishing Thyme Companies, a newly formed parent entity designed to build a portfolio of new, independent businesses in oncology that address persistent barriers to better cancer care. Grounded in data, enabled by technology, and built on trusted partnerships, Thyme Companies is positioned to take on oncology's biggest challenges. Areas under active development include accelerating the adoption of lower-cost biosimilars and improving clinical trial accrual, where slow enrollment limits patient access to beneficial trials and slows drug development. The first of these businesses is expected to launch later this year.

To support this next phase of growth, Thyme Care co-founder Robin Shah will serve as executive chairman of Thyme Companies leading the strategy and development of new businesses and working closely with his co-founder Bobby Green, M.D. to bring the connected, patient-first approach that built Thyme Care, to a broader set of healthcare challenges. Thyme Care continues under CEO Brad Diephuis, M.D., with Dr. Green as president and chief medical officer. Thyme Care remains the anchor of the Thyme Companies family of businesses; its name, partnerships, and member experience unchanged.

"When we founded Thyme Care, our vision was never limited to one part of cancer care. We wanted to create a better oncology care system," says Shah. "Thyme Care showed it could be done, and as we've grown alongside patients, providers and health plans, we've gained a deep perspective on the challenges that get in the way of better care. Thyme Companies is the next step in this journey, enabling us to build new solutions fully informed by what we've learned, while continuing to invest in the core business that made it possible."

About Thyme Companies

Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it. To learn more, visit thymecompanies.com.

About Thyme Care

Thyme Care aligns accountability across the cancer care journey, coordinating patients, providers, and health plans around a shared model of care that drives better outcomes and lower costs for everyone. Through dedicated care teams and technology, Thyme Care integrates directly into existing workflows to support patients longitudinally, close gaps between visits, and align clinical decisions with financial accountability. To learn more, visit thymecare.com.

Inkhouse for Thyme Care

thymecare@inkhouse.com

SOURCE Thyme Care

Share this article

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Deloitte has been recognized as a Leader in the IDC MarketScape: Worldwide Managed Detection Response/Managed Extended Detection and Response for the Enterprise 2026 Vendor Assessment (doc # US54792426, August 2026). Deloitte is one of seven vendors included in the Leaders Category among the 20 vendors evaluated by the IDC MarketScape.

According to the IDC MarketScape, "buyers are no longer satisfied with dashboards full of alerts and a monthly report. They are asking harder questions about analyst quality, SLA reliability under real stress, and whether GenAI investment inside the security operations center (SOC) is translating into better outcomes or simply faster-looking ones."

To help organizations build business-led resilience, Deloitte goes beyond traditional SOC services by aligning security objectives with broader business operations for enterprises. Deloitte professionals work alongside security leaders to demonstrate how cybersecurity is a business enabler, so leaders can be confident their businesses are protected against evolving threats. This approach is supported by an AI-enabled agentic SOC that helps to reduce false positives and helps accelerate response times, across a scalable and globally standardized architecture.

"As client needs move beyond fundamental security protections, security leaders increasingly expect their managed security collaborators to deliver specialized knowledge, outcome-driven AI innovation, and true strategic collaboration," says Ayan Chatterjee, Deloitte Global Cyber leader. "We believe Deloitte's MXDR team is positioned to help meet these expectations with deep security knowledge, differentiated capabilities, AI-driven SOC capabilities, and a dedication to measurable client outcomes."

"Backed by our security specialists, Deloitte is integrating Agentic AI capabilities to enhance threat detection, accelerate alert triage, and support faster remediation across security operations," says Chris Richter, Deloitte Global Detect and Response Product leader. "Combined with Deloitte's global delivery capabilities and deep industry expertise, these innovations help organizations address sector-specific threats, help to meet evolving regulatory requirements, and strengthen cyber resilience."

According to the IDC MarketScape, Deloitte's key strengths include:

- Multidisciplinary integration and business-aligned security operations: Deloitte sees its ability to connect MXDR to business transformation, regulatory obligations, and enterprise resilience as a key differentiator. Adjacency to audit, risk, compliance, M&A, and industry advisory practices enables framing detection outcomes in business impact terms. This integration is valued by customers undergoing digital transformation (DX) or regulatory alignment, where MXDR must align with strategic objectives. Coordinated delivery across identity modernization, crisis management, and vulnerability management reduces fragmentation if these capabilities are delivered by disparate teams.

- Measurable AI-driven impact with audited quality assurance: Deloitte's AI deployment delivers quantifiable productivity improvements that customers recognize as material value. Transparency around AI efficacy measurement includes measures such as tracking false positive rates, alert processing time, and analyst time savings. These measures provide confidence in their AI-augmented decisions. Deloitte reviews 20–30% of AI-processed alerts to validate accuracy and maintain feedback loops for retraining models. This approach addresses automation concerns and reinforces trust in AI-assisted workflows.

- Vendor-agnostic architecture with technology partnership ecosystem: Deloitte's platform-agnostic architecture supports broad SIEM, EDR, XDR, and analytics platforms without vendor lock-in.

- Global delivery with localized regulatory and industry expertise: Deloitte's combination of centralized Cybersphere Centers and distributed satellites delivers consistent SOC quality while accommodating country-specific regulatory requirements, data residency, and language needs. Customers in highly regulated sectors or multiple geographies value Deloitte's ability to align MXDR with sector-specific compliance frameworks and regional reporting. Industry depth in financial services, energy, healthcare, manufacturing, and government provides contextual awareness of sector threats, informing detection tuning and response.

Discover how Deloitte's MXDR services can help strengthen your cyber resilience, accelerate threat detection, and enhance your organization's security operations by visiting the Deloitte Global page for Managed Extended Detection & Response.

For more information about Deloitte Analyst Relations, please visit our Analyst Relations page.

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte provides leading professional services to nearly 90% of the Fortune Global 500® and thousands of private companies. Our people deliver measurable and lasting results that help reinforce public trust in capital markets and enable clients to transform and thrive. Building on its 180+-year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte's over 470,000 people worldwide work together every day to make an impact that matters at www.deloitte.com.

SOURCE Deloitte Global

Share this article

CovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.

QIDONG, China, Sept. 2, 2026 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio"), a leading innovator in bio‑based materials, announces a successful production of its first series of commercial on spec batches of Xatryx.T bioTHF and Xatryx® bioPTMEG. Concurrently, the company, in collaboration with globally renowned insole brand INSITE®, will unveil the world's first athletic insole featuring Xatryx® bioPTMEG, a non‑food bio‑based material, at the NW Materials Show in Portland, Oregon. This marks a successful application development milestone, showcasing Xatryx® bioPTMEG's application from a raw material to a bio‑based footwear building block.

Xatryx® Qidong Plant Mass Production On Spec

Following the mechanical completion of its inaugural 50,000 ton commercial plant for its C4 platform technology in April 2026, CovationBio has rapidly advanced to successful production. In August 2026, the Qidong plant officially initiated the production of its first commercial batches, including Xatryx.T bioTHF as well as Xatryx® bioPTMEG series products in molecular weights of 2000, 1800, and 1000. Under rigorous internal quality control testing, all produced grades adhere to industry expected quality specifications.

Mr. You Feifeng, Chairman of CovationBio, commented, "From mechanical completion to the first commercial batches being on spec, the CovationBio team completed the entire process of equipment commissioning, process optimization, and scale‑up in just four months. The initial on‑spec status of all three molecular weight grades demonstrates the maturity and stability of our proprietary process technology. We are actively collaborating with downstream customers for trial sampling and collecting feedback, which will further validate the performance of our products in end‑use applications and their drop-in adaptability to existing application processes."

As a sustainable alternative to fossil‑based PTMEG, Xatryx® bioPTMEG can directly replace fossil‑based PTMEG, delivering outstanding product performance in downstream applications such as spandex, polyurethanes, and thermoplastic elastomers while significantly reducing reliance on non‑renewable materials.

Key sustainability advantages of the Xatryx® product include:

- Significantly lower greenhouse gas emissions from manufacturing compared to fossil‑based counterparts;

- Bio‑based content derived from annually renewable non‑food biomass (e.g., agricultural by‑products such as corncobs), avoiding competition with food supply;

- Reduced dependence on non‑renewable fossil fuels;

- Drop‑in solution for downstream customers, requiring no major process adjustments when switching to bio‑based materials.

INSITE ® and CovationBio® Collaborate to Deliver the First Partially Bio‑Based Athletic Insole made with Xatryx®

Alongside the production milestone, CovationBio is actively collaborating with the value chain to develop various downstream applications of Xatryx®. On September 2–3, 2026, at the NW Materials Show in Portland, CovationBio will co‑host the "Next‑Generation Bio‑Based Footwear Materials Application Forum" with INSITE®, a globally recognized insole brand, and officially introduce the world's first partially non‑food bio‑based athletic insole with Xatryx®.

This innovative insole product uses Xatryx® bioPTMEG as its core raw material, extending non‑food bio‑based materials from industrial feedstock to everyday athletic footwear. INSITE®, with its deep expertise in footwear biomechanics and podiatric design, joins forces with CovationBio in this cross‑industry collaboration, setting a new benchmark for sustainable materials in the insole industry.

Dr. Zhao Mosha, Global Marketing Director of CovationBio's C4 Platform, stated, "From the on‑spec mass‑production of Xatryx® at Qidong plant to the end‑product launch at the Portland footwear show, together with INSITE® we have achieved the leap from 'raw materials to end use' within just a few weeks. This is not only a technological milestone for both companies, but also a great example that with the drop-in capability of Xatryx® to replace fossil-based incumbent and the whole value chain innovative collaboration, the non‑food bio‑based material industry can move from concept to reality very efficiently. We look forward to joining hands with INSITE® and value‑chain partners of more applications to drive the sustainable transformation of the materials industry."

The NW Materials Show is one of the most influential professional exhibitions in the global footwear materials and functional fabrics sector. At the event, the CovationBio team will explain how Xatryx® empowers the footwear material supply chain and how it will work with global value‑chain partners to advance sustainable development strategies.

About CovationBio®

Covation Biomaterials LLC (CovationBio®) was established in 2022 and is headquartered in Newark, Delaware. The company possesses advanced and innovative technologies in the bio‑based materials field, focusing on offering a portfolio of high‑performance and sustainable solutions. Building on DuPont's pioneering scientific innovation legacy, CovationBio provides innovative solutions for industries in apparel, footwear, and carpet. Through its brands which include Xatryx® and Sorona®, CovationBio delivers essential materials that help create bio‑based products within reach for every customer.

CovationBio®, Xatryx® and Sorona® are trademarks of Covation Biomaterials or its affiliates.

Disclaimer: The above statements regarding greenhouse gas emissions assessment and product performance are based on internal testing results conducted by Covation Biomaterials LLC using representative methods. Actual results may vary depending on specific application scenarios and conditions of use.

Share this article

CovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.

QIDONG, China, Sept. 2, 2026 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio"), a leading innovator in bio‑based materials, announces a successful production of its first series of commercial on spec batches of Xatryx.T bioTHF and Xatryx® bioPTMEG. Concurrently, the company, in collaboration with globally renowned insole brand INSITE®, will unveil the world's first athletic insole featuring Xatryx® bioPTMEG, a non‑food bio‑based material, at the NW Materials Show in Portland, Oregon. This marks a successful application development milestone, showcasing Xatryx® bioPTMEG's application from a raw material to a bio‑based footwear building block.

Xatryx® Qidong Plant Mass Production On Spec

Following the mechanical completion of its inaugural 50,000 ton commercial plant for its C4 platform technology in April 2026, CovationBio has rapidly advanced to successful production. In August 2026, the Qidong plant officially initiated the production of its first commercial batches, including Xatryx.T bioTHF as well as Xatryx® bioPTMEG series products in molecular weights of 2000, 1800, and 1000. Under rigorous internal quality control testing, all produced grades adhere to industry expected quality specifications.

Mr. You Feifeng, Chairman of CovationBio, commented, "From mechanical completion to the first commercial batches being on spec, the CovationBio team completed the entire process of equipment commissioning, process optimization, and scale‑up in just four months. The initial on‑spec status of all three molecular weight grades demonstrates the maturity and stability of our proprietary process technology. We are actively collaborating with downstream customers for trial sampling and collecting feedback, which will further validate the performance of our products in end‑use applications and their drop-in adaptability to existing application processes."

As a sustainable alternative to fossil‑based PTMEG, Xatryx® bioPTMEG can directly replace fossil‑based PTMEG, delivering outstanding product performance in downstream applications such as spandex, polyurethanes, and thermoplastic elastomers while significantly reducing reliance on non‑renewable materials.

Key sustainability advantages of the Xatryx® product include:

- Significantly lower greenhouse gas emissions from manufacturing compared to fossil‑based counterparts;

- Bio‑based content derived from annually renewable non‑food biomass (e.g., agricultural by‑products such as corncobs), avoiding competition with food supply;

- Reduced dependence on non‑renewable fossil fuels;

- Drop‑in solution for downstream customers, requiring no major process adjustments when switching to bio‑based materials.

INSITE ® and CovationBio® Collaborate to Deliver the First Partially Bio‑Based Athletic Insole made with Xatryx®

Alongside the production milestone, CovationBio is actively collaborating with the value chain to develop various downstream applications of Xatryx®. On September 2–3, 2026, at the NW Materials Show in Portland, CovationBio will co‑host the "Next‑Generation Bio‑Based Footwear Materials Application Forum" with INSITE®, a globally recognized insole brand, and officially introduce the world's first partially non‑food bio‑based athletic insole with Xatryx®.

This innovative insole product uses Xatryx® bioPTMEG as its core raw material, extending non‑food bio‑based materials from industrial feedstock to everyday athletic footwear. INSITE®, with its deep expertise in footwear biomechanics and podiatric design, joins forces with CovationBio in this cross‑industry collaboration, setting a new benchmark for sustainable materials in the insole industry.

Dr. Zhao Mosha, Global Marketing Director of CovationBio's C4 Platform, stated, "From the on‑spec mass‑production of Xatryx® at Qidong plant to the end‑product launch at the Portland footwear show, together with INSITE® we have achieved the leap from 'raw materials to end use' within just a few weeks. This is not only a technological milestone for both companies, but also a great example that with the drop-in capability of Xatryx® to replace fossil-based incumbent and the whole value chain innovative collaboration, the non‑food bio‑based material industry can move from concept to reality very efficiently. We look forward to joining hands with INSITE® and value‑chain partners of more applications to drive the sustainable transformation of the materials industry."

The NW Materials Show is one of the most influential professional exhibitions in the global footwear materials and functional fabrics sector. At the event, the CovationBio team will explain how Xatryx® empowers the footwear material supply chain and how it will work with global value‑chain partners to advance sustainable development strategies.

About CovationBio®

Covation Biomaterials LLC (CovationBio®) was established in 2022 and is headquartered in Newark, Delaware. The company possesses advanced and innovative technologies in the bio‑based materials field, focusing on offering a portfolio of high‑performance and sustainable solutions. Building on DuPont's pioneering scientific innovation legacy, CovationBio provides innovative solutions for industries in apparel, footwear, and carpet. Through its brands which include Xatryx® and Sorona®, CovationBio delivers essential materials that help create bio‑based products within reach for every customer.

CovationBio®, Xatryx® and Sorona® are trademarks of Covation Biomaterials or its affiliates.

Disclaimer: The above statements regarding greenhouse gas emissions assessment and product performance are based on internal testing results conducted by Covation Biomaterials LLC using representative methods. Actual results may vary depending on specific application scenarios and conditions of use.

SOURCE Covation Biomaterials LLC

Share this article

Bringing hardware design and verification in-house, MulticoreWare expands its silicon-to-solution capabilities from architecture to production.

SAN JOSE, Calif., Sept. 2, 2026 /PRNewswire/ -- MulticoreWare, Inc., a global technology company delivering AI software solutions, accelerated computing technologies, and advanced engineering services, today announced the acquisition of Simulus Automation Pvt. Ltd., a semiconductor design and verification specialist serving customers developing SoCs, chipsets, and accelerator technologies.

The industry is shifting toward hardware-software co-design. Today's heterogeneous System-on-Chips (SoCs) are expanding beyond traditional CPU, GPU, DSP, and NPU architectures to integrate programmable logic (FPGAs) directly into the SoC fabric, bringing power advantages and flexibility. Managing high-speed data across these architectures requires solving connectivity bottlenecks.

To meet this transformation, MulticoreWare is integrating Simulus Automation's hardware capabilities with its legacy of high-performance software engineering. This acquisition bridges the gap between silicon design, verification, and software deployment, creating a unified pipeline from architecture to production.

"The semiconductor industry is entering a new era driven by heterogeneous compute, intelligent edge devices, and autonomous systems. Bringing Simulus into the MulticoreWare family ensures our clients can benefit from tightly integrated design pipelines, maximize power efficiency, solve interconnect challenges, and accelerate time-to-market," said AGK Karunakaran, President & CEO, MulticoreWare.

This acquisition enhances MulticoreWare's capabilities across:

FPGA-Native High-Performance Engineering: MulticoreWare completes its heterogeneous compute portfolio by combining its CPU, GPU, DSP, and NPU expertise with native FPGA capabilities. With expertise in High-Level Synthesis (HLS) and RTL implementations, the team supports sensor fusion and Physical AI workloads for edge and robotics applications.

Advanced Connectivity Protocols (CXL & PCIe): As data transfer becomes a constraint in advanced SoCs, solving connectivity is paramount. The acquisition brings extensive design and verification expertise in CXL and PCIe protocols, enabling high-bandwidth, low-latency interconnects for distributed processing.

Cloud FPGA Scalability: The combined engineering force expands MulticoreWare's ability to distribute repetitive workloads onto Cloud FPGAs, enabling customers to deploy and emulate AI workloads with global hyperscalers.

"Joining MulticoreWare creates exciting opportunities for our employees and customers. By combining Simulus' design verification expertise with MulticoreWare's global semiconductor and AI capabilities, we can deliver even greater value to customers developing the next generation of silicon platforms," said Karthick Gopal, CEO of Simulus Automation.

As demand for AI infrastructure, spatial intelligence, industrial automation, and edge computing grows, the combined organization will help customers address complex silicon and software challenges.

About MulticoreWare

MulticoreWare, Inc. delivers AI software solutions and engineering services for Physical AI, Agentic AI, Robotics, Edge Intelligence, and Accelerated Computing. With expertise in multimodal AI, Vision-Language-Action (VLA) models, sensor perception and fusion, AI optimization, embedded systems, and high-performance software, MulticoreWare helps customers transform AI technologies into production-ready solutions. Its technologies support applications across automotive, robotics, industrial automation, smart cities, healthcare, defense, and edge devices, while its video codec technologies enable video experiences worldwide.

About Simulus Automation

Simulus Automation Pvt. Ltd. is a semiconductor engineering company specializing in design verification, connectivity protocol IP (PCIe, CXL), FPGA development, and engineering services for advanced SoCs, chipsets, accelerators, and high-performance computing platforms.

Media Contact:

Suchithra Thyagarajan

VP - Corporate Marketing

marcom@multicorewareinc.com  

SOURCE MulticoreWare Inc.

Share this article

COSTA MESA, Calif., Sept. 2, 2026 /PRNewswire/ -- Synoptek, a leading systems integrator and managed service provider, today announced it has been recognized as a Microsoft Fabric Featured Partner. This designation is awarded to a select group of Microsoft partners who have demonstrated deep technical expertise, proven customer implementations, and a strong track record of delivering successful outcomes on the Microsoft Fabric platform.

To earn this recognition, Synoptek met Microsoft's qualification criteria, including required certifications, validated client implementation telemetry, and other performance benchmarks that reflect real-world delivery experience with Microsoft Fabric.

"Achieving Fabric Featured Partner status is a testament to our team's technical expertise and our track record of delivering measurable outcomes for clients, said Shail Rathi, Practice Director, Data Insights at Synoptek. We're proud of this recognition and excited to build on it."

As a Fabric Featured Partner, Synoptek helps organizations modernize data platforms, unify analytics environments, and prepare data environments for advanced analytics and AI workloads using Microsoft Fabric's integrated capabilities across data engineering, data science, real-time intelligence, and business intelligence.

Synoptek's Fabric practice covers the full analytics lifecycle on the platform, including Lakehouse and Warehouse design using the Medallion architecture, OneLake-based data centralization, Data Factory pipeline orchestration, real-time intelligence with KQL databases and Eventstreams, Power BI integration with OneLake Delta tables, semantic modeling, and end-to-end data governance. The team also helps organizations migrate from legacy Synapse, Databricks, and on-premises platforms to Fabric with validated parity and minimal disruption, and applies AI capabilities such as Copilot and Azure AI Foundry integration to accelerate reporting, data engineering, and governance workflows.

These recognitions represent distinct areas of Fabric expertise. The Fabric Featured Partner designation reflects proven capability across the core Fabric platform, spanning data integration, data engineering, and analytics delivery. The Fabric RTI (Real-Time Intelligence) Featured Partner designation is awarded specifically for demonstrated expertise in real-time workloads, including event stream ingestion, real-time data processing, and visualization through real-time dashboards and Data Activator. The Fabric Databases Featured Partner designation recognizes proven experience implementing Fabric's database capabilities, a newer addition to the platform that brings transactional data into the same governed environment as the rest of an organization's analytics estate. Together, the three designations reflect the breadth of Synoptek's technical expertise across Fabric's core platform, real-time intelligence, and database capabilities.

About Synoptek

Synoptek is the first global Managed Experience Provider (MxP™), delivering end-to-end IT and digital transformation services that align technology performance with business outcomes. Powered by its aiXops platform, Synoptek provides advisory, integration, and AI-activated managed services across four core pillars: Cloud & Agile Infrastructure, Business Applications & Platforms, Customer & Employee Experience, and Cybersecurity. With 24/7 global delivery, deep industry expertise, and a holistic strategy-to-operations model, Synoptek helps organizations reduce operational burden, accelerate transformation, and continuously evolve their digital capabilities.

SOURCE Synoptek

Share this article

USDT0 Goes Live on Stellar, Connecting Unified Dollar Liquidity to the World's Most Accessible Network

ROAD TOWN, British Virgin Islands, Sept. 2, 2026 /PRNewswire/ -- USDT0, the infrastructure that brings the most widely used stablecoin Tether (USDT) to every network, is now live on Stellar, the world's most accessible network. This deployment connects one of the longest-running networks for real-world payments and cross-border finance directly into USDT0's growing borderless liquidity. As a result, Stellar now has access to a unified dollar asset, enabling stablecoin movement across networks without fragmentation, wrappers, or third-party bridges.

"Stellar has already proven its value as payments infrastructure," said Lorenzo Romagnoli, Co-Founder of USDT0. "USDT0 extends that utility by connecting Stellar to Tether's global dollar liquidity and making it available wherever users and capital need to move. That opens up a much bigger future for builders on Stellar: payment firms, fintechs, and treasury teams can serve global markets without rebuilding dollar liquidity network by network. Stellar becomes a stronger base for financial products designed to serve many different use cases and ecosystems."

Since launching in January 2025, the USDT0 Network has facilitated over $100 billion in total value moved across 29 connected blockchain ecosystems, reflecting sustained, production-scale usage of its unified liquidity model. Against that backdrop, Stellar was designed to move real value across borders. The network prioritizes predictable settlement, minimal fees, and support for issued assets, characteristics that have translated into years of real-world activity across payments, aid distribution, and consumer financial services.

"Stellar has been trusted to power cross-border payments for more than a decade and the addition of USDT0 to the Stellar ecosystem strengthens the network's industry-leading payments stack," said Denelle Dixon, CEO & Executive Director of the Stellar Development Foundation. "Together, the Stellar network and USDT0 are leading the way toward a global financial system where trillions will move onchain."

Built on LayerZero's OFT Standard, USDT0 does not introduce another bridged or wrapped representation. Instead, the deployment anchors USDT0 directly within Stellar's asset model while connecting it to the same unified liquidity framework used across other major ecosystems. USDT0 on Stellar is now available on BiLira Kripto, Bitget Wallet, Fireblocks, Freighter, Kraken, Kredete, Lobstr, Meru, Ramp Network, and SushiSwap, with additional partners such as Exodus expected to go live shortly.

For the Stellar ecosystem, this means:

- Unified liquidity: Access to the same global USDT liquidity layer shared across multiple chains.

- Seamless cross-chain movement: Stablecoin balances can move into and out of Stellar without custodial bridges or isolated pools.

- Simpler integrations for builders: Payment flows, DeFi applications, and treasury systems can be built around a single, consistent USDT asset.

In addition to introducing the world's most widely used stablecoin to Stellar, USDT0 advances how liquidity behaves across the ecosystem, making cross-chain movement a feature aligned with the network's focus on interoperability and practical onchain finance.

For more than a decade, Stellar has demonstrated that blockchains can support real financial activity at global scale, processing more than $40B so far in 2026. The integration connects Stellar's purpose-built design with the next phase of stablecoin infrastructure, combining unified liquidity with proven execution to support what stablecoins are becoming.

Learn more about USDT0 and get started at usdt0.to/transfer or follow USDT0 on Twitter @USDT0.

About USDT0

USDT0 is the infrastructure that brings Tether's dollar and gold assets to every network, giving builders and institutions on every chain access to Tether's stablecoin and gold liquidity. From seamless transactions and settlement to collateral, treasury, and programmable rails for AI and autonomous systems, USDT0 advances Tether as the default asset issuer for the future of finance. Supported assets include USDT, Tether's dollar-backed stablecoin, and XAUT0, which brings Tether Gold to every network backed 1:1 by physical gold held in Swiss vaults.

About Everdawn Labs

Everdawn Labs is a premier software development consultancy, specializing in crafting bespoke software solutions that drive innovation, efficiency, and growth in the digital asset ecosystem.

About LayerZero

LayerZero is where finance and the internet converge. It makes any token or application compatible with every type of blockchain. From protocols to institutions, organizations use LayerZero to build, issue, and scale digital assets and products. It connects 170+ blockchains, processes millions of messages a year, and powers billions in value transfer. Trusted by PayPal USD, Ethena, the State of Wyoming, BitGo, and more, LayerZero has become the standard for building on blockchains.

The Stellar Network

The Stellar network is a decentralized, fast, scalable, and uniquely sustainable blockchain built for financial products and services. It offers builders smart contracts functionality and a protocol optimized for payments, with a design intended to keep fees low and to provide transaction speeds that can scale with increased adoption. Financial institutions and innovators worldwide issue assets and settle payments on the Stellar network, which has processed billions of operations with millions of accounts since the network was first launched.

DISCLAIMER

This press release is for informational purposes only and does not constitute an offer, solicitation, or recommendation of any security, token, digital asset, or financial product, nor does it constitute investment, legal, tax, or financial advice.

This press release contains forward-looking statements based on current expectations and assumptions, including statements regarding anticipated availability, functionality, adoption, and transaction volumes. Actual results may differ materially due to risks, uncertainties, and changing circumstances. No party named herein undertakes any obligation to update such statements.

USDT0 and USDT are issued and managed by third parties. The Stellar Development Foundation does not issue, custody, redeem, or guarantee any digital asset referenced herein and makes no representation regarding reserves, backing, solvency, regulatory status, or continued availability of any such asset. All figures relating to market capitalization, transaction volume, and value transferred are sourced from third parties, have not been independently verified, and are subject to change.

The regulatory status of stablecoins and digital assets varies by jurisdiction and is subject to change. Users are responsible for determining compliance with applicable laws. Availability of USDT0 through any referenced exchange or wallet is subject to that platform's terms, eligibility requirements, and regulatory approvals.

The Stellar Development Foundation provides open-source software and does not control the Stellar network, which is operated by independent, decentralized validators.

SOURCE USDT0

Share this article

BPI Bundesverband der Pharmazeutischen Industrie

Pharmadialog: Diskussion über AMNOG-Änderungen positives Signal!

Berlin (ots)

Zur Fortsetzung des Pharmadialogs und die Diskussion um AMNOG 2.0 erklärt der BPI-Hauptgeschäftsführer Dr. Kai Joachimsen:

"Kritik am GKV-Beitragssatzstabilisierungsgesetz (BStabG) ist mehr als berechtigt. Gleichwohl ist es ein positives Signal, wenn sich das Bundesgesundheitsministerium jetzt mit erforderlichen Änderungen am AMNOG beschäftigt. Der BPI unterstützt das und wirkt daran mit. Wir müssen das AMNOG gemeinsam weiterentwickeln, und bürokratische Belastungen im Verfahren abbauen. Allerdings dürfen die Gespräche und Verhandlungen darüber die Folgen der US-amerikanischen Pharmapolitik sowie des BStabG nicht ausblenden. Die dort beschlossenen Sparmaßnahmen stehen in einem deutlichen Spannungsverhältnis zur langfristigen Sicherung von Innovation und Patientenzugang. Es wird deshalb nicht ausreichen, AMNOG-Anpassungen zu diskutieren, während sich die Rahmenbedingungen für Markteinführung und Verfügbarkeit von Innovationen verschlechtern.

Aus BPI-Sicht sind mit Blick auf den AMNOG-Prozess folgende Punkte wichtig: bessere Anerkennung besonderer Therapiesituationen und bestverfügbarer Evidenz in der Zusatznutzenbewertung, mehr Verlässlichkeit bei Beratungen zur zweckmäßigen Vergleichstherapie mit der zusätzlichen regelhaften Abfrage relevanter Endpunkte bei den Fachgesellschaften sowie eine EU-HTA-Umsetzung, die Doppelarbeit vermeidet und Synergien nutzt. Nur so kann Bürokratieabbau mit Innovationsförderung, Planungssicherheit und dem schnellen Zugang von Patientinnen und Patienten zu innovativen Arzneimitteln gegen häufige und seltene Erkrankungen verbunden werden."

Pressekontakt:

Hermann Hofmann, Tel. 0176 127909-36, presse@bpi.de

Original-Content von: BPI Bundesverband der Pharmazeutischen Industrie, übermittelt durch news aktuell